The company develops bergamot-based products (BergaMet Pro+, BergaMet Mega+O, etc.) and plant-based health technology neuro-products for brain health under brands like UBN ACTIVATE and UBN RELIEF. The company achieved strong revenue growth (up 21% year-over-year in Q3 2025) while reaching its fourth consecutive positive cash flow quarter. A transformative acquisition of Gummy USA (August 2025) was projected to generate up to $7 million in additional annualized revenue.
Cyborg Score Rationale
Healthy Extracts demonstrates solid operational traction with multiple consecutive positive cash flow quarters and strong revenue growth in 2025 (up 21-35% YoY). However, the micro-cap structure ($21M market cap as of May 2026), minimal employee base (~22 employees), and continued net losses present significant execution and scaling risks. The patented IP and subscription-based recurring revenue model offer strategic differentiation.